Dr. Uwe Gottschalk / Chief Technology Officer Pharma/Biotech, Lonza AG, Basel, Switzerland

Uwe Gottschalk is Chief Technology Officer (CTO) at Lonza Pharma/Biotech since June 2014.

Before joining Lonza he served as Group Vice President at Sartorius Stedim Biotech between 2004 and 2014 with a global responsibility for all bioseparation-related process technology. He worked in different capacities for Bayer Health Care from 1991 to 2004, overseeing the process development and manufacturing  of biopharmaceutical products such as monoclonal antibodies and other recombinant proteins.

Uwe earned his M.Sc and PhD in Chemistry at the University of Münster, Germany and Notting- ham, UK, delivering his dissertation on drug targeting with monoclonal antibodies. He has written extensively in the areas of downstream processing, industrial biotechnology and somatic gene therapy. In academia, Dr. Gottschalk is currently Head Lecturer at the University of Duisburg- Essen (Germany) and also lectured at the Ecole Polytechnique Fédérale de Lausanne (EPFL) in Lausanne (Switzerland).

Dr. Gottschalk was board member of the VBU Association of German Biotech Companies between 2006 and 2010. He sits on the editorial advisory boards of Pharmaceutical Bioprocessing, Ge- netic Engineering News and BioPharm International. He is honorary member of the Society for BioChromatography and Nanoseparations, member of the Management Pool at the Institut of Marketing, University of St. Gallen (HSG) and member of the American Chemical Society (ACS).